Ewald Wöll1, Josef Thaler2, Felix Keil3, Birgit Gruenberger4, Michael Hejna5, Wolfgang Eisterer6, Michael A Fridrik7, Hanno Ulmer8, Vera Trommet2, Florian Huemer9, Lukas Weiss9, Richard Greil9. 1. St. Vinzenz Krankenhaus Betriebs GmbH, Zams, Austria e.woell@krankenhaus-zams.at. 2. Department of Internal Medicine IV, Klinikum Wels-Grieskirchen GmbH, Wels, Austria. 3. 3rd Medical Department, Hanusch Hospital, Vienna, Austria. 4. St. John of God's Hospital, Vienna, Austria. 5. Medical University of Vienna, Vienna, Austria. 6. Medical University Hospital Innsbruck, Innsbruck, Austria. 7. Kepler Universitätsklinikum GmbH, Med Campus III, Klinik für Interne, Linz, Austria. 8. Department of Medical Statistics, Informatics and Health Economics, Innsbruck Medical University, Innsbruck, Austria. 9. IIIrd Medical Department at the Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria.
Abstract
BACKGROUND/AIM: Although high response rates using the doublet-chemotherapy of oxaliplatin and irinotecan as well as its combination with cetuximab in advanced gastric cancer were shown in previous trials, time to progression was short, suggesting acquired chemotherapy resistance. PATIENTS AND METHODS: Sequential chemotherapy (oxaliplatin and irinotecan followed by docetaxel) combined with bevacizumab was investigated in the GASTRIC-3 trial. Patients achieving at least stable disease were continued on maintenance bevacizumab. RESULTS: Objective response rate was available in 33 patients: Complete response (CR) 12.1%, partial response (PR) 39.4%, stable disease (SD) 27.3%. Median time to progression was 7.0 months (95%CI=5.0-11.0) and median overall survival was 11 months (95%CI=9.0-15.0). Of note, two patients continue to receive bevacizumab maintenance therapy for more than 5 years with ongoing CR. CONCLUSION: Combining sequential chemotherapy with oxaliplatin/irinotecan and docetaxel with bevacizumab followed by bevacizumab maintenance is feasible and clinically active in advanced gastric cancer. Copyright
BACKGROUND/AIM: Although high response rates using the doublet-chemotherapy of oxaliplatin and irinotecan as well as its combination with cetuximab in advanced gastric cancer were shown in previous trials, time to progression was short, suggesting acquired chemotherapy resistance. PATIENTS AND METHODS: Sequential chemotherapy (oxaliplatin and irinotecan followed by docetaxel) combined with bevacizumab was investigated in the GASTRIC-3 trial. Patients achieving at least stable disease were continued on maintenance bevacizumab. RESULTS: Objective response rate was available in 33 patients: Complete response (CR) 12.1%, partial response (PR) 39.4%, stable disease (SD) 27.3%. Median time to progression was 7.0 months (95%CI=5.0-11.0) and median overall survival was 11 months (95%CI=9.0-15.0). Of note, two patients continue to receive bevacizumab maintenance therapy for more than 5 years with ongoing CR. CONCLUSION: Combining sequential chemotherapy with oxaliplatin/irinotecan and docetaxel with bevacizumab followed by bevacizumab maintenance is feasible and clinically active in advanced gastric cancer. Copyright
Authors: Mihaela Chivu-Economescu; Lilia Matei; Laura G Necula; Denisa L Dragu; Coralia Bleotu; Carmen C Diaconu Journal: World J Gastroenterol Date: 2018-05-14 Impact factor: 5.742